US medical devices industry saw a drop of 26.61% in overall deal activity during April 2022, when compared with the last 12-month average, led by ArchiMed’s $1.2bn private equity deal with Natus Medical, according to GlobalData’s deals database.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 80 deals worth $2.8bn were announced in April 2022, compared with the 12-month average of 109 deals.
venture financing was the leading category in the month in terms of volume with 61 deals, which accounted for 76.3% of all deals.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIn second place was M&A with 16 deals, followed by private equity with three transactions, respectively accounting for 20% and 3.8% of overall deal activity in the US technology industry during the month.
In terms of value of deals, venture financing was the leading deal category in the US medical devices industry with total deals worth $1.24bn, while private equity and M&A deals totalled $1.2bn and $334.7m respectively.
US medical devices industry deals in April 2022: Top deals
The top five medical devices industry deals accounted for 73.6% of the overall value during April 2022.
The combined value of the top five medical devices deals stood at $2.04bn, against the overall value of $2.8bn recorded for the month.
The top five medical devices industry deals of April 2022 tracked by GlobalData were:
1) ArchiMed $1.2bn private equity deal with Natus Medical
2) The $300m venture financing of Biofourmis by CVS Health,Export Development Bank of Iran,General Atlantic,Mass Mutual Ventures,Openspace Ventures,Sequoia Capital and SoftBank Vision Fund II
3) Adams Street Partners,Altimeter Capital Management,Battery Ventures,Coatue,Dragoneer Investment Group and ICONIQ Growth $220m venture financing deal with Reify Health
4) The $170m acquisition of Inform Diagnostics by Fulgent Genetics
5) Impact Investment Partners,Japan Industrial Partners and NEC $150m venture financing deal with BostonGene
